Aug 20, 2025 • Benzinga
SOMEWHAT-BULLISH
James Hardie Stock Is Trading Lower Wednesday: What's Going On? - James Hardie Industries ( NYSE:JHX )
James Hardie misses earnings and sales estimates in the first quarter. Operating income is down 41% and net income is down 60%. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more. Unlock all ratings now.
Aug 20, 2025 • Benzinga
NEUTRAL
Nasdaq Down 1%; Lowe's Posts Upbeat Earnings - Calidi Biotherapeutics ( AMEX:CLDI ) , Guess ( NYSE:GES )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 200 points on Wednesday. The Dow traded down 0.07% to 44,891.07 while the NASDAQ fell 1% to 21,101.73. The S&P 500 also fell, dropping, 0.47% to 6,381.22. Consumer staples shares jumped by 1.1% on ...
Aug 20, 2025 • Benzinga
SOMEWHAT-BULLISH
Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesday - Allstate ( NYSE:ALL ) , Custom Truck One Source ( NYSE:CTOS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities raised Keysight Technologies, Inc. KEYS price target from $175 to $179.
Aug 20, 2025 • Benzinga
NEUTRAL
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Celldex Therapeutics ( NASDAQ:CLDX ) , Alcon ( NYSE:ALC )
U.S. stock futures were slightly lower this morning, with the S&P 500 futures falling around 0.1% on Wednesday. Shares of La-Z-Boy Incorporated LZB fell sharply in pre-market trading as the company reported weaker-than-expected financial results for the first quarter of fiscal 2026.
Aug 20, 2025 • Benzinga
NEUTRAL
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Color Star Tech ( NASDAQ:ADD ) , Aspen Insurance Hldgs ( NYSE:AHL )
Shares of Rocket Pharmaceuticals, Inc. RCKT rose sharply in pre-market trading after the company disclosed that the FDA has lifted the clinical hold on the pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. Rocket Pharmaceuticals shares jumped 15.8% to $3.37 in the pre-market ...
Aug 19, 2025 • Motley Fool
NEUTRAL
James Hardie Q1 Sales Fall 9 Percent
James Hardie Industries ( NYSE:JHX ) reported first-quarter fiscal 2026 results on August 19, 2025, with global net sales of $900 million, down 9% year over year, and adjusted EBITDA of $226 million at a 25.1% margin. The company completed its acquisition of AZEK, more than doubling its ...